Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)

10/19/2021 | 04:08pm EST
Item 1.01. Entry into a Material Definitive Agreement.
Extension of Existing Lease Agreements
On October 13, 2021, Exagen Inc. (the "Company") entered into the Second
Amendment of Lease (the "1221 Lease Extension") with Liberty Vista to amend the
Standard Industrial/Commercial Single-Tenant Lease, dated August 15, 2014, by
and between Geiger Court, LLC (later assigned to Liberty Vista) and the Company
(the "1221 Lease"), relating to office space located at 1221 Liberty Way, Vista,
CA 92081, which is located adjacent to the Company's headquarters. The 1221
Lease Extension extends the term of the 1221 Lease from January 31, 2026 to
April 30, 2027. The 1221 Lease Extension provides that the base monthly rent for
the leased space shall be $22,470 for the 12-month period beginning on February
1, 2026 and $23,594 for the period from February 1, 2027 through April 30, 2027.
On October 19, 2021, the Company entered into the Fifth Addendum (the "1261
Suite B/C Lease Extension") to the Standard Industrial/Commercial Multi-Tenant
Lease, dated January 13, 2012, by and between RGS Properties and the Company
(the "1261 Suite B/C Lease"), relating to the Company's headquarters. The 1261
Suite B/C Lease Extension extends the term of the 1261 Suite B/C Lease from
January 31, 2026 to April 30, 2027. The 1261 Suite B/C Lease Extension provides
that the base monthly rent for the leased space shall be $20,084.42 for the
period between February 1, 2026 and April 30, 2027.
On October 19, 2021, the Company entered into the First Addendum (the "1261
Suite A Lease Extension") to the Standard Industrial/Commercial Multi-Tenant
Lease, dated February 27, 2020, by and between RGS Properties and the Company
(the "1261 Suite A Lease"), relating to office and laboratory space in the
building attached to the Company's headquarters. The 1261 Suite A Lease
Extension extends the term of the 1261 Suite A Lease from January 31, 2026 to
April 30, 2027. The 1261 Suite A Lease Extension provides that the base monthly
rent for the leased space shall be $14,750.63 for the period between February 1,
2026 and April 30, 2027.
The foregoing description of the 1221 Lease Extension, 1261 Suite B/C Lease
Extension and 1261 Suite A Extension do not purport to be complete and are
qualified in their entirety by reference to the full text of the 1221 Lease
Extension, 1261 Suite B/C Lease Extension, and 1261 Suite A Extension,
respectively, which will be filed as exhibits to the Company's Quarterly Report
on Form 10-Q to be filed for the quarter ending September 30, 2021.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant.
The disclosure set forth under Item 1.01 of this Current Report on Form 8-K is
incorporated into this Item 2.03 by reference.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about EXAGEN INC.
11/17Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
GL
11/17Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
GL
11/11KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating
MT
11/10EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K
PU
11/10Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M
MT
11/10Earnings Flash (XGN) EXAGEN Posts Q3 Loss $-0.42, vs. Street Est of $-0.47
MT
11/10EXAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/10Exagen Inc. Reports Third Quarter 2021 Results
AQ
11/10Exagen Inc. Provides Revenue Guidance the Full Year 2021
CI
More news
Analyst Recommendations on EXAGEN INC.
More recommendations